Background
Methods
Search strategy and selection criteria
We searched the MEDLINE, as well as BioRxiv and MedRxiv preprint servers for original research describing or using an animal model of SARS-CoV-2 induced COVID published in English from January 1, 2020, to May 20, 2020. We used the search terms (COVID-19) OR (SARS-CoV-2) AND, (animal models), (hamsters), (nonhuman primates), (macaques), (rodent), (mice), (rats), (ferrets), (rabbits), (cats), and (dogs). The preprint servers were included in the search as the field of COVID-19 is developing quickly. Inclusion criteria were the establishment of animal models of COVID-19 as an endpoint. Other inclusion criteria were assessment of prophylaxis, therapies, or vaccines, using animal models of COVID-19. Exclusion criteria consisted of reviews, non-original articles, and unrelated to the COVID-19 infection or experimental animals that do not support SARS-CoV-2 replication. 101 studies and 326 preprints were screened of which 13 peer-reviewed studies and 14 preprints were included in the final analysis (Fig. 1). The variables extracted were the population type, study aim, the virus strain used, clinical response, pathology, viral replication, and host response as well as the effects of prophylaxis, drugs, or vaccines. The outcomes were organized according to species and categorized into phenotype (signs or symptoms; histopathology, time-course of the illness and outcome), viral (titer in each tissue organ, detection methods, duration of positivity), and host response (dynamic of seroconversion, inflammatory, and hemostatic markers), therapy, and vaccine (efficacy and safety) |
Results
Species (ref) | Number age (gender) | Virus strain dose* (inoculation route)† | Clinical signs & observation duration (DPI) § | Viral replication‡ (DPI) | Pathology & sacrificing date (DPI) | Immune response | Seroconversion (DPI) | Outcome measures |
---|---|---|---|---|---|---|---|---|
Rhesus macaques | n = 8 | SARS-CoV-2 nCoV-WA1–2020 | Fever | Nose, oropharynx, lung | Anemia | At 1 dpi only, significant increases in IL1ra, IL6, IL10, IL15, MCP-1, MIP-1b | IgG antibody anti-spike protein (10) | Pathogenesis of COVID-19 |
Adults | Weight loss | Rectum (1) | Mild to moderate, interstitial pneumonia, | |||||
Munster et al. (2020) [37] | (M/F) | 4 × 105 TCID50 (IT, IN, PO) | Dyspnea Tachypnea | Edema | ||||
Piloerection | Hyaline membranes formation | At 3 dpi decrease in TGFα | ||||||
Reduced appetite | Hyperplasia type II pneumocytes | |||||||
Hunched posture | Swollen mediastinal lymph nodes (3, 4, 21) | |||||||
Pale appearance | ||||||||
Dehydration (21) | ||||||||
Rhesus macaques | n = 3 | BetaCoV/Wuhan/IVDC-HB-01/2020 | Weight loss | Nose, oropharynx, lung | Interstitial pneumonia | Decreased CD4+ T and CD8+ T cells in young and old. | IgG antibody anti- SARS-CoV-2 (14) | Pathogenesis of COVID-19 in aging animals |
3–5 years | Asthenia | Rectum, alveolar epithelia | Inflammation | |||||
Yu et al. (2020) [38] | n = 2 | 1 × 106 TCID50 (IT) | More severe in old than young (14) | Macrophages (3) | Edema | |||
15 years (NA)‖ | Higher replication in old than young | More severe in old than young (7) | ||||||
Rhesus macaques | n = 4 per group (6 vaccinated groups) | DNA vaccine** | NA‖ (14) | Lowest BAL levels of viral RNA with full-length S protein encoding vaccine | NA | Upregulation IFN-γ antipeptide spike proteins. | IgG antibody anti- SARS-CoV-2 (day14 post-vaccination) | Evaluation of candidate DNA vaccine |
IM at week 0 and week 3 | ||||||||
Yu et al. (2020) [39] | 6–12 years (M/F) | 1.1 × 104 PFU (IN and IT) (day 21 post-vaccine) | S1 and RBD lower response than other variant Spike proteins** | |||||
n = 10 sham control | 1.1 × 104 PFU (IN and IT) | High BAL levels of viral RNA | NA | Anamnestic humoral and cellular immune responses including IFN-γ ELISPOT responses | NA | |||
6–12 years (M/F) | ||||||||
Rhesus macaques | n = 6 vaccine | 2.5 × 1010 ChAdOx1 nCoV-19 (IM) | Tachypnea (3/6), dyspnea (2/6), | Nose, BAL (2/6) | NO | Upregulation of IFN-γ (1) | IgG antibody anti-SARS-CoV-2 spike protein (day 14 post-vaccination) | Evaluation of DNA vaccine |
M/F | SARS-CoV-2 nCoV-WA1-2020 | Ruffled fur (1/6) (7) | Lung (very low), oropharynx, mediastinal, duodenum (3) | |||||
2.6 × 106 TCID50 (IT, IN, PO, CJ) (day 28 post-vaccine) | No BAL subgenomic viral RNA | No difference in TNF-α, IL-2, IL-4, IL-6, and IL-10 vaccine vs. control | ||||||
Van Doremalen et al. (2020) [40] | n = 3 control` | Vaccinated with 2.5 × 1010 ChAdOx1 GFP (IM) | Tachypnea (3/3) Ruffled fur (2/3) Diarrhea (1/3) Pale appearance (1/3) | BAL, nasal swabs, lung, cervical, mediastinal lymph nodes, duodenum, urinary bladder | Interstitial pneumonia (2 of 3) | TNF-α, IL-2, IL-4, IL-6, and IL-10 | NA | |
Thickening of alveolar septae | ||||||||
M/F` | Red nose (1/3) | Edema | ||||||
SARS-CoV-2 nCoV-WA1-2020 | BAL subgenomic viral RNA (3, 5) | Hyperplasia type I & II pneumocytes syncytial cells | ||||||
2.6 × 106 TCID50 (IT, IN, PO, CJ) (day 28 post-vaccine) | No extra pulmonary injury | |||||||
Rhesus macaques | n = 4 per vaccine group | PiCoVacc 6 μg/dose (high) or 3 μg/dose (low) at 0, 7, and 14 days (IM) | NA | Pharyngeal, anal, and pulmonary (3) | Mild and focal histopathological changes both lower lobes | No differences CD3+, CD4+, CD8+, TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6 vaccine vs. control | IgG antibody anti-SARS-CoV-2 (day 14 post-vaccination) | Evaluation of an inactivated vaccine |
3–4 years (M/F) | SARS-CoV-2-2/human/CHN/CN1/2020 | |||||||
1 × 106 TCID50 (IT) (day 22 post-vaccine) | ||||||||
Gao et al. (2020) [41] | n = 4 control | Vaccinated with Al(OH)3 adjuvant (sham) or physiological saline (control) at 0, 7, and 14 days | NA (7) | Oropharynx, crissum, lung, rectum (3) | Severe interstitial pneumonia | CD3+, CD4+, CD8+, TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6 | ||
3–4 years (M/F) | IM | |||||||
SARS-CoV-2-2/human/CHN/CN1/2020 | ||||||||
1 × 106 TCID50 (IT) (22 days post-vaccine) | ||||||||
Rhesus macaques | n = 6 | SARS-CoV-2 nCoV-WA1-2020 | Dyspnea (1/6) (7) | Nose, oropharynx, lung (1) | Minimal interstitial pneumonia subpleural spaces (3/6) (7) (7) | NA | NA | Testing of antiviral therapy |
Remdesivir | Low BAL titers (1) | |||||||
(M/F) | 2.6 × 106 TCID50 (IT, IN, OC, PO) | No virus in BAL (3) | No extra pulmonary injury | |||||
Williamson, B.N. et al. (2020) [42] | n = 6 control | Vehicle solution | Tachypnea, dyspnea | Nose, oropharynx, lung, and BAL (1) | Multifocal, mild to moderate, interstitial pneumonia (7) | NA | NA | |
(M/F) | SARS-CoV-2 CoV-WA1–2020 | No extra pulmonary injury | ||||||
2.6 × 106 TCID50 (IT, IN, OC, PO) | ||||||||
Rhesus macaques | n = 9 | SARS-CoV-2 USA-WA1/2020 | Reduced appetite (35) | Nose, pharynx, trachea, lung, gastrointestinal tract, liver, kidney, pneumocytes I & II, ciliated bronchial epithelial cells (1) | Acute interstitial pneumonia | Neutropenia | IgG anti- SARS-CoV-2 Spike protein (35) | Immune protection after a second exposure |
Consolidation | Lymphopenia (mild and transitory in high dose group) | |||||||
6–12 years | initial inoculation | Edema | IFN-γ upregulation | |||||
1.1 × 106, n = 3 | Multiple Inflammatory foci | |||||||
(M/F) | 1.1 × 105, n = 3 | Hyaline membranes | ||||||
1.1 × 104 PFU, n = 3 | Damage to type I and type II pneumocytes | |||||||
(IN, IT) | Necrotic bronchiolar epithelium | |||||||
Bronchiolar epithelial syncytial cells | ||||||||
No extra pulmonary injury | ||||||||
Chandrashekar et al. (2020) [43]c | n = 9 | SARS-CoV-2 USA-WA1/2020 | No (14) | 5 log10 reduction BAL & nasal viral loads (1) | NA | Increased virus-specific Nab titers | ||
Second inoculation | ||||||||
day 35 post-initial infection | ||||||||
6–12 years | 1.1 × 106 | |||||||
1.1 × 105 | ||||||||
(M/F) | 1.1 × 104 PFU (IN, IT) | |||||||
Rhesus macaques | n = 7 | SARS-CoV-2 | Fever | Nose, oropharynx, lung, gut, spinal cord, bladder, rectum (3) | Thickened alveolar septa | Increase CD4+ T cells | IgG antibody anti-SARS-CoV-2 (14) | Immune protection after a second exposure |
WH-09/hum/2020 | Weight loss | Macrophages accumulation in alveoli Degeneration alveolar epithelia | ||||||
3–5 years | Posture change | Inflammatory infiltrates (5, 7) | ||||||
Initial inoculation | Rapid breathing | |||||||
(NA) | 1 × 106 TCID50 (IT) | Reduced appetite (28) | ||||||
Bao et al. (2020) [44] | (n = 4) | SARS-CoV-2 | Transient temperature increase (14) | Negative | No pathology (5) | CD4+ T higher at 7 day post-exposure vs. post-initial exposure | Higher IgG antibody anti-SARS-CoV-2 (14) vs. initial exposure | |
WH-09/hum/2020 | ||||||||
3–5 years | ||||||||
(NA) | second inoculation day 28 post-initial infection | |||||||
1 × 106 TCID50 (IT) | ||||||||
Rhesus macaques | (n = 5) | SARS-CoV-2 WH-09/hum/2020 | weight loss (IT route) (21) | Nasal, oropharynx, rectum (IG route) | Interstitial pneumonia (IT route) | NA | IgG anti-SARS-CoV-2 on 21 dpi (CJ route) | Viral infection routes |
Conjunctival (CJ route) | Mild interstitial pneumonia (CJ route) | |||||||
Deng, W. et al. (2020) [45] | 3–5 years (M) | 1 × 106 TCID50 (IT, CJ, IG) | Lung, ileum, caecum (IT) (1) | No pneumonia (IG route) (7) | ||||
Rhesus macaques | n = 4 young | SARS-CoV-2 CDC, Guangdong, China | Fever | Nose, oropharynx, trachea | Inflammatory cell infiltrates | Peak CD4+ T cells, CD8+ T cells, and monocytes (2) | IgG antibody anti-SARS-CoV-2 (4) | Pathogenesis of COVID-19 in different species of nonhuman primates |
n = 6 adult | Weight loss (21) | Bronchus, lung, rectum | Diffuse hemorrhage and necrosis | |||||
n = 4 old | Blood, spleen (2) | Swollen lymph nodes (hilar, mediastinal, mesenteric) | ||||||
4.75 × 106 PFU (IT, IN, CJ) | Pericardial effusion | Young stronger B cell responses vs. adults vs. old | IgG levels lower in young vs. adult vs. old | |||||
(NA) | (50% given to young) | Mild hepatic steatosis | Increased G-CSF, IL-1A, IL-8, IL-15, IL-18, MCP-1, MIP-1B, sCD40-L | |||||
splenic hemorrhage (4, 7, 12, 13, 15) | ||||||||
Common Marmoset | n = 6 | SARS-CoV-2 | None | Nose, oropharynx, rectum | Broken pulmonary septum | NA | No | |
CDC, Guangdong | Blood (2) | Inflammatory infiltrates | ||||||
Age = NA (M/F) | 1 × 106 PFU (IN) | Splenic hemorrhage | ||||||
Swollen hepatocytes | ||||||||
Renal inflammatory infiltrate | ||||||||
Cynomolgus macaques | n = 6 | SARS-CoV-2 CDC, Guangdong | Fever | Nose, oropharynx, trachea | Inflammatory cell infiltrates | CD4+ T cells, CD8+ T cells, and monocytes (2) | IgG antibody anti-SARS-CoV-2 (4) | |
Weight loss | Bronchus, lung, rectum | Diffuse hemorrhage and necrosis | ||||||
Adult | 4.75 × 106 PFU (IT, IN, PO) | Blood, spleen (2) | Swollen lymph nodes (hilar, mediastinal) | Young stronger B cell responses vs. adults vs. old | ||||
Hepatic steatosis | ||||||||
Lu et al. (2020) [46] | (M/F) | Splenic hemorrhage | Increased G-CSF, IL-1A, IL-8, IL-15, IL-18, MCP-1, MIP-1B, sCD40-L | |||||
Cynomolgus macaques | n = 4 | SARS-Cov-2 BetaCoV/Munich/BavPat1/2020 | serous nasal discharge (1/4 old monkey) (21) | Nose, oropharynx, lung | Foci pulmonary consolidation | NA | IgG antibody anti-SARS-CoV-2 (14) | Comparisons of pathogenesis between COVID-19, SARS-CoV and MERS-CoV |
Pneumocytes I & II | Diffuse alveolar damage | |||||||
4–5 y (F) | Ciliated nasal, bronchial & bronchiolar epithelial cells | Hyaline membrane | ||||||
15–20 years (F) | 2 × 105 TCID50 (IT, IN) | Multinucleated giant cells | ||||||
Type I & II pneumocytes hyperplasia | ||||||||
Earlier detection in young (2) vs. old (4). | Alveolar edema | |||||||
Leukocyte infiltration | ||||||||
Higher nasal replication in old vs. young | (4) | |||||||
Rockx et al. (2020) [48] | n = 10 | MERS-CoV | No | Nose, oropharynx, lung | Foci pulmonary consolidation | IgG antibody anti-MERS-CoV (21) | ||
EMC strain, accession no. NC_019843 | Pneumocytes II | Alveolar edema | ||||||
3–5 years | 106 TCID50 | & rectal swabs (2) | Leukocyte infiltration | |||||
Type II pneumocytes hyperplasia | ||||||||
F | (IT, IN) | |||||||
NA | NA | No | Nose, oropharynx, lung | Type I & II pneumocytes hyperplasia | NA | NA | ||
Pneumocytes I & II | Alveolar edema (aged only) | |||||||
Leukocyte infiltration | ||||||||
Hyaline membrane (aged only) | ||||||||
Cynomolgus macaques | n = 6 | 2019-nCoV/USA-WA1-A12/2020 | None (30) | Nose, eye, oropharynx, rectum (2) | CT scan: Ground glass appearance | Increased CXCL8, IL6, IL13, IL15, IL1RN, and TNF (6) in one macaque. | IgG antibody anti-SARS-CoV-2 spike S1 subunit (10) | Evaluation of medical interventions |
Reticulonodular opacities | ||||||||
Finch et al. (2020) [47] | 4–4.5 years (M/F) | 3.65 × 106 PFU (IT, IN) | Peri-bronchial thickening | |||||
Subpleural nodules | ||||||||
Alveolar dense consolidation (n = 1) | ||||||||
PET scan: FDG uptake lung and regional lymph nodes (2), mediastinal lymph nodes and spleen (6) | ||||||||
African green monkey | n = 6 | SARS-CoV-2-2/INMI1-/2020/Italy | Reduced appetite | Nasal, oropharynx, lung, rectum, pneumocytes I & II, alveolar macrophages (2) | Interstitial pneumonia | Increased CRP ¶ (n = 2) | IgG antibody against SARS-CoV-2 b (5) | Pathogenesis of COVID-19 |
Bronchiolitis | ||||||||
Fever (31) | ||||||||
Woolsey et al. (2020) [49] | NA | 5 × 105 PFU (IT, IN) | Edema | IL-8, IP-10, IL-12, IL-6, IFN-beta, IL10, and MCP-1 (2) | ||||
Hemorrhage | ||||||||
Hyaline membrane | ||||||||
Hyperplasia type II pneumocytes | ||||||||
Distention and flaccidity small intestines segments (5) |
Species (ref) | Number age (gender) | Virus strain dose* (inoculation route)† | Clinical signs & observation duration (DPI) § | Viral replication‡ (DPI) | Pathology & sacrificing date (DPI) | Immune response | Seroconversion (DPI) | Outcome Measures |
---|---|---|---|---|---|---|---|---|
Mice | WT-BALB/c, n = 3 | 2 × 105 TCID50 of P 4†† or 2 × 106 of P 6†† (IN) | NA | Lung (3) | Mild lung pathology (2) | Mild inflammatory response | NA | Interferon response to SARS-CoV-2 infection |
BALB/c: | SCID, n = 3 | (14) | No difference in viral load WT vs. SCID | No difference in lung pathology WT vs. SCID (2, 4, 7, 14) | ||||
WT¶ | ||||||||
SCID|| | 6–8 weeks (F) | |||||||
C57BL/6: | C57BL/6 n = 5 | 2 × 105 TCID50 of P 4 or 2 × 106 of P 6 (IN) | NA (14) | Lung (3) | Greater intra-alveolar hemorrhage and peribronchiolar inflammation in IFNar1−/− mice than WT and IL28r−/− mice (3) | Higher inflammatory response in IFNar1−/− vs. WT and IL28r−/− mice | NA | |
WT | IFNar1−/−¶¶ n = 14 | |||||||
Ifnar1−/− | Higher viral replication in IFNar1−/− mice vs. WT and IL28r−/− mice | (2, 4, 7, 14) | ||||||
Il28r−/− | 6–8 weeks (F) | |||||||
Boudewijns et al. (2020) [56] | C57BL/6, n = 5 | 2 × 105 TCID50 of P 4 or 2 × 106 of P 6 (IN) | NA (14) | Lung (3) | Mild lung pathology (3) | Mild inflammatory response | NA | |
IL28r−/−, n = 5 | No difference in viral load between WT and IL28r−/− | (2, 4, 7, 14) | ||||||
6–8 weeks (F) | ||||||||
Mice | hACE2 mice | SARS-CoV-2 (BetaCoV/Wuhan/IVDC-HB-01/2020|EPI_ISL_402119) | Slight | Highest viral load | Moderate interstitial pneumonia | MAC2, CD3+ T and CD19+ B cells in alveolar septum | IgG antibody response against SARS-CoV-2 (21) | Pathogenesis of COVID-19 |
hACE2‖‖ transgenic mice | (ACE2-HB-01) | Bristles | In lung (3) | Thickened alveolar septa | ||||
Weight loss | Intestine (1) | |||||||
n = 19 | 105 TCID50 (IN) | Arched back (14) | Alveolar macrophage, and alveolar epithelia (3) | Lymphocytes, macrophages, and monocytes infiltrates in the interstitial and alveolar space | ||||
6–11 months (M/F) | ||||||||
Bronchioles degeneration (3) | ||||||||
No pathology in intestine, spleen, heart, liver, kidney, brain, and testis | ||||||||
(1, 3, 5, 7) | ||||||||
Bao et al. (2020) [50] | WT-HB-01 (n = 15) | SARS-CoV-2 (BetaCoV/Wuhan/IVDC-HB-01/2020|EPI_ISL_402119) 105 TCID50 (IN) | No (14) | No viral RNA detectable in lung or intestine (1) | No (1, 3, 5, 7) | No | No | |
6–11 months (M/F) | ||||||||
Mock-treated hACE2 mice (n = 15) | PBS 50 μl (IN) | No (14) | No viral RNA detectable in lung or intestine | No (1, 3, 5, 7) | No | No | ||
6–11 months (M/F) | ||||||||
Mice | n = 5 6–8 weeks (M) | SARS-CoV-2 (BetaCoV/Hong Kong/VM20001061/2020 [KH1]) | NA | NA | NA | NA | IgG antibody response against SARS-CoV and SARS-CoV-2 spike protein and RBD | Cross-reactivity of antibodies against SARS-CoV and SARS-CoV-2 |
Infection | SARS-CoV (HK39849, SCoV) | |||||||
105 PFU (IN) | ||||||||
BALB/c: | n = 5 | Immunization with heat-inactivated plasma from SARS-CoV and SARS-CoV-2 (IP) | NA | NA | NA | NA | Cross-reactive antibody binding responses SARS-CoV-2 and SARS-CoV No cross-neutralization SARS-CoV-2 and SARS-CoV | |
WT | 6–8 weeks (M) | |||||||
Lv et al. (2020) [53] | Immunization | |||||||
n = 6 | Vehicle (IN) | NA | NA | NA | NA | |||
6–8 weeks (M) control | ||||||||
Transgenic mice | n = 7 | SARS1/SARS2-RdRp §§ | Improvement of pulmonary function | reduced lung viral load 102 PFU/lobe (5) | Decreased lung hemorrhage (5) (5) | NA | NA | Antiviral therapy testing |
C57BL/6***: | 17 weeks (F) | 103 PFU (IN) | (5) | |||||
Ces1c−/− | Remdesivir given at 1dpi | |||||||
Pruijssers et al. (2020) [55] | Remdesivir | |||||||
n = 7 | SARS1/SARS2-RdRp | Reduced pulmonary function by WPH††† (5) | Lung viral load | Lung hemorrhage (5) (5) | NA | NA | ||
17 weeks (F) | 103 PFU (IN) | 105 PFU/lobe (5) | ||||||
Control | Vehicle | |||||||
n = 3 | Mouse-adapted SARS-CoV-2 (BetaCoV/Wuhan/AMMS01/2020) | Weight loss old mice (5) (7) | Trachea, lung, heart, liver, and intestine, pneumocytes Type II | Thickened alveolar septa | Increased TNF-α, IL-1β, IL-6, and IL-5, MCP-1, G-CSF, and GM-CSF (3) | NA | Establishment of mouse-adapted SARSCoV-2 model of COVID19 | |
Young, 6 weeks (F) | Alveolar damage and focal exudation | |||||||
Hemorrhage, | ||||||||
n = 3 | 7.2 × 105 PFU (IN) | Viral replication similar in old vs. young cells (3) | Inflammatory cell infiltration | Higher and sustained cytokines levels in aged mice vs. young | ||||
Denaturation of endothelial tissues (3) | ||||||||
Mice | Old, 9 months (F) | Lung pathology similar in old vs. young mice (3, 5, 7) | ||||||
BALB/c: | ||||||||
WT | Control mice | NA | No weight loss | No viral protein | NO | NO | Evaluation of candidates vaccine | |
Gu et al. (2020) [54] | NA | |||||||
n = 10 | Immunization day 1, 14 | NA | No viral replication detectable in lungs (5) | No | NA | Higher IgG antibody response against SARS-CoV-2 (14) | ||
6–8 weeks | Challenged with mouse adapted SARS-CoV-2 | |||||||
Immunized with SARS-CoV-2 RBD-Fc protein | (IN), 4 weeks after second immunization | |||||||
PBS control with aluminum adjuvant | High viral load in the trachea and lungs (5) | Focal perivascular and peribronchiolar inflammation Thickened alveolar septa | NA | NA | ||||
Mice | n = 5 | SARS-CoV-2 | No (2) | No viral replication detectable in lung (2) | NA | NA | IgG1 ab1 protects hACE2 transgenic mice from SARS-CoV-2 infection. (2) | Evaluation of prophylaxis with monoclonal antibody |
6–9 weeks (F) | 105 PFU (IN) | |||||||
C3B6: hACE2 mice | ||||||||
Immunization | Human monoclonal IgG1 antibody (12 h) | |||||||
C3B6: | Prior the virus challenges (IP) | |||||||
hACE2 transgenic mice | n = 6 | SARS-CoV-2 | No (2) | Viral replication 103 PFU per lung (2) | NA | NA | No | |
6–9 weeks (F) | 105 PFU (IN) | |||||||
C3B6: hACE2 mice | ||||||||
BALB/c mice | Control | IgG1 m336 (no activity in vitro) | ||||||
Li et al. (2020) [51] | Balb/c, n = 5 | Mouse ACE2 adapted SARS-CoV-2‡‡ | No (2) | No viral replication detectable in lung lobe at different dosages (2) | NA | NA | IgG1 ab1 protected mice SARS-CoV-2 challenge (2) | |
10–12 months (F) | ||||||||
105 PFU (IN) | ||||||||
Human monoclonal IgG1 ab1 antibody (12 h) | ||||||||
Prior the virus challenges (IP) | ||||||||
Mice | hACE2 mice | SARS-CoV-2 | Weight loss | Lung (2), brain (5) | NA (2, 5) | NA | NA | Evaluation of vaccine and therapy in mouse-adapted SARS-CoV-2 model |
BALB/c: And hACE2 | NA | 105 PFU (IN) | Mortality 40% (5) (5) | |||||
Transgenic mice | BALB/c mice | SARS-CoV-2MA§ | Pulmonary obstruction (WBP)††† | Upper airway | NA | NA | ||
Dinnon et al. (2020) [52] | n = 33 | 105 PFU (IN) | Lung (2,4) | Greater lung inflammation and hemorrhage in old vs. young mice (2,4) | ||||
Young 12 weeks | ||||||||
BALB/c mice | Greater | Higher replication in old vs. young mice | ||||||
n = 34 | Weight and pulmonary | |||||||
12 months | Function loss in old vs. young mice | |||||||
Vaccination | SARS-CoV-2 spike (S) or nucleocapsid (N) | NA | Vaccine with spike S reduced lung and nasal turbinate titer (2) | NA | NA | NA | ||
n = 8–10 | ||||||||
10 weeks | Challenged 4 weeks post-inoculation with SARS-CoV-2 MA | |||||||
BALB/c | 105 PFU (IN) | |||||||
Prophylaxis | Subcutaneous administration interferon (IFN) lambda-1a 2 μg | Reduced SARS-CoV-2 MA replication in the lung (2) | NA | NA | NA | |||
Therapy | 18 h prior or 12 h after | |||||||
BALB/c | SARS-CoV-2 MA | |||||||
12 weeks | 105 PFU (IN) | |||||||
n = NA |
Species (ref) | Number age (gender) | Virus strain dose* (inoculation route)† | Clinical signs & observation duration (DPI) § | Viral replication‡ (DPI) | Pathology & sacrificing date (DPI) | Immune response | Seroconversion (DPI) | Outcome measures |
---|---|---|---|---|---|---|---|---|
Syrian hamsters Chan et al. (2020) [57] | n = 8 | SARS-CoV-2 Hong Kong | Tachypnea | Nose, trachea, lung | Diffuse alveolar damage (exudative) | Upregulation of Interferon-γ and proinflammatory chemokine, cytokine genes expression | IgG antibody response against SARS-CoV-2 (7) | Viral transmission and immunoprophylaxis |
Weight loss | Intestine (high viral load¶) (2–7) | |||||||
6–10 weeks (M/F) (Donor) | 105 PFU (IN) | Lethargy | Apoptosis | |||||
Ruffled furs | Blood (low viral load) | Diffuse alveolar damage (proliferative) | Early convalescent serum Immunoprophylaxis decreased nasal and lung viral load but not lung pathology or clinical signs | |||||
Hunched back posture (14) | Tissue repair | |||||||
Intestinal villi damage and necrosis | ||||||||
Reduced spleen size (2–14) (2, 4, 7, 14) | ||||||||
n = 8 | Direct contact with donor | Less weight loss than inoculated animals (14) | No difference in viral load inoculated animals vs. infected animals via contact (4) | No difference inoculated vs. infected by contact (2, 4, 7, 14) | NA | IgG antibody response against SARS-CoV-2 (7) | ||
6–10 weeks (M/F) | Inoculated with 100 ul of PBS | |||||||
Syrian hamsters | n = 6 (mAb CC12.1 or CC12.23) ¶ | SARS-CoV-2 (USAWA1/2020) | Weight loss dose-dependent (5) | Reduced lung viral load | NA (5) | NA | Neutralizing antibody (5) | Immunoprophylaxis and therapy |
1X106 PFU (IN) | ||||||||
12 h post-Ab infusion | ||||||||
Rogers et al. (2020) [58] | n = 6 Control IgG1 (Den3) ‖ | SARS-CoV-2 (USAWA1/2020) | Weight loss (5) | No difference in lung viral loads control vs. low dose groups | NA (5) | NA | NA | |
1 × 106 PFU (IN) | ||||||||
12 h post-Ab infusion | ||||||||
Golden Syrian hamsters | (n = 9)) 4–5 weeks (M) (Donor) | SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 | Weight loss (6) | Upper respiratory tract, nose, olfactory | Inflammatory infiltrates nasal turbinate Progressive lung consolidation (5 to 60%) Mononuclear cell infiltration. | CD3 positive T lymphocytes in peribronchial region (5) | IgG antibody response against SARS-CoV-2 (14) | Viral transmission |
Ruffled hair coat (5) (14) | Neurons, bronchus, lung | No extrapulmonary pathology | ||||||
Kidney, duodenum | ||||||||
8 × 104 TCID50 (IN) | No pathology in the intestine, spleen, heart, and brain (2, 5, 7) (2, 5, 7) | |||||||
Sia et al. (2020) [59] | (n = 9) | Infection via contact with donor hamster | Weight loss (6) | Detectable infectious viruses (9/9) | NA | NA | IgG antibody response against SARS-CoV-2 (14) | |
4–5 weeks (M) | Ruffled hair coat day (4) (14) | Day 1 post-contact | ||||||
(Contact) | No difference in viral shedding contact vs. donor | |||||||
Syrian hamster | (n = 7) | SARS-CoV-2 (BetaCoV/Belgium/GHB03021/2020) | NA (4) | Lungs, blood, spleen, liver, upper & lower gastrointestinal tract | Multifocal necrotizing bronchiolitis, | Increased inflammation-related gene expression | NA | Host interferon response to SARS-CoV-2 |
Age: NA (F) | 2 × 105 TCID50 (P4 virus) or 2 × 106 TCID50 (P6 virus) (IN) | Leukocyte infiltration | ||||||
Wild type | Edema (4) (2, 3, 4) | No increase in serum levels of IL-6, IL-10, and IFN-γ (4) | ||||||
Hamster (STAT2−/− and IL28R-a −/−) strains | (n = 7) | Same as wild type | NA (4) | Greater levels of viral RNA in the lung, spleen, liver, blood, and upper and lower gastrointestinal tract in STAT2−/− hamster vs. WT and IL28ra−/− | Lung pathology and inflammation decreased in (STAT2−/−) but not in IL28R-a−/− hamsters (2,3,4) (2, 3, 4) | Increased IL-6 and IL-10 expression in lungs | NA | |
7–12 weeks (F) | No increase in serum levels of IL-6, IL-10, and IFN-γ (4) | |||||||
STAT2−/− | ||||||||
Boudewijns et al. (2020) [56] | (n = 7) | Same as wild type | NA (4) | Lungs, blood, spleen, liver, upper, & lower gastrointestinal tract | Bronchopneumonia and peribronchiolar inflammation (2,3,4) (2, 3, 4) | High (MMP)-9 levels in lung homogenates compare to WT | NA | |
5–7 weeks (F) | ||||||||
No differences in lung viral RNA levels in WT, vs. STAT2−/− vs. IL28R-a−/− hamsters | Increased IL-6 and IL- | |||||||
IL28R-a−/− | 10 expression in lungs | |||||||
No increase in serum levels of IL-6, IL-10 and IFNγ (4) |
Species (ref) | Number age (gender) | Virus strain dose* (inoculation route)† | Clinical signs & observation duration (DPI)§ | Viral replication‡ (DPI) | Pathology & sacrificing date (DPI) | Immune response | Seroconversion (DPI) | Outcome measures |
---|---|---|---|---|---|---|---|---|
Ferrets | n = 12 | NMC-nCoV02/Korea | Increased body temperature | Nose, saliva, urine, and feces | Acute bronchiolitis | NA‡ | IgG and serum-neutralizing antibody response against SARS-CoV-2 (12) | Pathogenesis of COVID-19 |
Infiltrates of immune cells and debris (4) | ||||||||
12–20 months | 105.5 TCID50 | Reduced activity ` | (4, 8, 12) | |||||
Assess viral transmission | ||||||||
M/F | IN | occasional coughs (12) | Trachea, lung, kidney, serum, and intestine (2) | |||||
n = 12 | Control | NO (12) | NO | NO (4, 8, 12) | NO | NO | ||
12–20 months | ||||||||
M/F | ||||||||
Kim et al. (2020) [60] | n = 6 (naïve direct contact) | Direct contact | Increased body temperature (12) | All animals were infected (2) | (12) | IgG and serum-neutralizing antibody response against SARS-CoV-2 (12) | ||
n = 6 (naïve indirect contact) | Indirect contacts | No increased body temperature (12) | Nose, feces (2 out of 6 animals) (4) | (12) | IgG antibody response against SARS-CoV-2 (12) Serum-neutralizing antibody response in 1 out of 6 | |||
Ferrets Blanco-Melo et al. (2020) [61] | n = 6 | USA-WA1/2020 | NA (14) | Nose, trachea | NA (3, 14) | Reduced interferon type I and III response | NA | Host interferon response |
4 months | 5 × 104 PFU | (3,7) | ||||||
Castrated male | IN | Increase proinflammatory chemokines and cytokines response | ||||||
Ferrets Richard et al. (2020) [62] | n = 4 | BetaCoV/Munich/BavPat1/2020 | NA (21) | Nose, throat, rectum | NA (21) | NA | IgG antibody response against SARS-CoV-2 (21) | Viral transmission |
6 months (F) | 6.105 TCID50 | |||||||
Donor | IN | |||||||
n = 4 | 6 h post-inoculation co-housed with donor | NA (21) | Nose, throat, rectum (1) | NA (21) | NA | IgG antibody response against SARS-CoV-2 (21) | ||
6 months (F) | ||||||||
direct contact | ||||||||
n = 4 | 1 dpi placed in an opposite cage (10 cm) of donor | NA (21) | Nose, throat, rectum (3) | NA (21) | NA | IgG antibody response against SARS-CoV-2 (21) | ||
6 months (F) | ||||||||
Indirect contact | ||||||||
Ferrets | n = 10 | SARS-CoV-2 /F13/environment/2020/Wuhan | Fever | Nose, throat, and rectum (low titer) (4–8) | Severe lymphoplasmacytic, perivasculitis | IgG antibody response against SARS-CoV-2 (13) | Pathogenesis of COVID-19 | |
3–4 months F | Loss of appetite (20) | Vasculitis | NA | |||||
SARS-CoV2/CTan/human/2020/Wuhan] | Increased type II pneumocytes, macrophages, and neutrophils in the alveolar septa and alveolar lumen. | |||||||
105 PFU | Mild peribronchitis (13) | |||||||
IN | (4, 20) | |||||||
n = 8 | SARS-CoV2/CTan/human/2020/Wuhan] | NA (14) | Nose, throat (2–8) | NA (2, 4, 8, 14) | NA | NA | ||
3–4 months | 105 PFU | |||||||
F | IT | |||||||
Cats | n = 10 | SARS-CoV-2 /CTan/human/2020/Wuhan | NA (20) | Nose, soft palate, tonsil, trachea, lungs, and small intestines. | NA (3, 6, 10, 20) | NA | IgG antibody response against SARS-CoV-2 (10) | |
6–9 months | 105 PFU | |||||||
M\F | IN | |||||||
Sub-adult | ||||||||
n = 10 | SARS-CoV-2 /CTan/human/2020/Wuhan | One cat died (3) (12) | Nose, soft palate, tonsil, trachea, lungs, and small intestines. | Extensive nasal, tonsil, tracheal, lung, and small intestine epithelial mucosal lesions (3) (3, 6, 11,12) | NA | IgG antibody response against SARS-CoV-2 (10) | ||
70–100 days | 105 PFU | |||||||
M/F | IN | |||||||
Juvenile | ||||||||
Dogs | n = 5 | SARS-CoV-2-2/CTan/human/2020/Wuhan | NA | Rectum (2/5) | NA | NA | IgG antibody response against SARS-CoV-2 (14) | |
3-month beagles | 105 PFU | |||||||
IN, | ||||||||
Shi et al. (2020) [63] | n = 2 | Exposed to donor | NA | No | NA | NA | No | |
3 month | ||||||||
Beagles |